Fundraising Fox
Stingraytx
Houston, US · Founded 2018 · 2 known investors
Find your way into Stingraytx
Each arrow is one introduction. Sign up to fill in the first one.
Ask David Arthur to introduce you to Jonathan P. Northrup
You →David · together at Salarius Pharmaceuticals →Jonathan
Sign up to find every way you can get introduced to Stingraytx
- Your email: who you already know at Stingraytx, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Stingraytx team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Stingray is an oncology-focused biotech company developing drugs from discovery through clinical development to commercialization, led by scientists and physicians with experience in building oncology companies.
Founders & leadership
Stingraytx was founded in 2018 by Jonathan Northrup and Sunil Sharma.
Investors · 2
Reported raises · per SEC filings
Form D private placements$8.6M disclosed across 4 rounds · 2020–2024
▶$25KraisedMay 2024 · 1 investors · BiotechnologyRule 506(b)
- Jonathan P. NorthrupExecutive Officer, Director
- Sunil SharmaExecutive Officer, Director
- Uma BhattExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $25K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$436.8KraisedFeb 2024 · 21 investors · BiotechnologyRule 506(b)
- Uma BhattExecutive Officer, Director
- Jonathan P. NorthrupExecutive Officer, Director
- Sunil SharmaExecutive Officer, Director
- Offering amount
- $450K
- Amount sold
- $436.8K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedDec 2023 · 52 investors · BiotechnologyRule 506(b)
- Jonathan P. NorthrupExecutive Officer, Director
- Sunil SharmaExecutive Officer, Director
- Uma BhattExecutive Officer, Director
- Offering amount
- $6.7M
- Amount sold
- $6.6M
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMay 2021 · 9 investors · BiotechnologyRule 506(b)
- Jonathan P. NorthrupExecutive Officer, Director, Promoter
- Scott Andrew JordanExecutive Officer, Director, Promoter
- Sunil SharmaExecutive Officer, Director, Promoter
- Offering amount
- $3M
- Amount sold
- $1.5M
- Sales commissions
- $32.5K
- Finders' fees
- $29.5K
- Proceeds to insiders
- $32.5K
- Placement agents
- Liberi Life Sciences Consultancy BV, Finalis Securities LLC
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Stingraytx do?
- Stingray is an oncology-focused biotech company developing drugs from discovery through clinical development to commercialization, led by scientists and physicians with experience in building oncology companies.
- Who founded Stingraytx?
- Stingraytx was founded by Jonathan Northrup, Sunil Sharma in 2018.
- Who are Stingraytx's investors?
- Stingraytx's investors include Catalytic Impact Foundation, Green Park & Golf Ventures.
- How much funding has Stingraytx raised?
- Stingraytx has disclosed $8.6M raised across 4 rounds.
- Where is Stingraytx headquartered?
- Stingraytx is headquartered in Houston, US.